Objective: To compare the extent of fetomaternal transfusion after amniocentesis and cordocentesis.
Setting: Three-hundred and forty-five amniocentesis and 268 cordocentesis were performed for genetic indications. The extent of fetomaternal transfusion was calculated on the basis of the maternal serum alpha-fetoprotein level changes.
Results: The mean fetomaternal transfusion was 6.3 and 62 μL in the amniocentesis and cordocentesis groups, respectively. Transplacental needle passage and longer procedural time were risk factors for fetomaternal transfusion. The frequency of transplacental passage was higher and the procedural time was longer in the cordocentesis group. The fetal loss rate was 1.17% after amniocentesis and 1.2% after cordocentesis, respectively.
Conclusions: Cordocentesis causes more injury to the extrafetal compartment, which results in a higher level of fetomaternal transfusion. However, though a nearly ten times higher fetomaternal transfusion was observed after cordocentesis, there was no essential difference in pregnancy outcome between the two groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11845-010-0663-3 | DOI Listing |
Transfusion
December 2024
Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Background: In 2010, Denmark was the first country to implement a targeted routine antenatal anti-D prophylaxis (tRAADP) program, offering fetal RHD genotyping to all nonimmunized D negative pregnant women. The program represented a shift from only postnatal prophylaxis to a combined antenatal and postnatal prophylaxis. This study aimed to evaluate the clinical effect of tRAADP in Denmark.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
January 2025
Immunohematology and Transfusion Centre, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Am J Perinatol
November 2024
Department of Obstetrics and Gynecology, Kaiser Permanente Northern California, Oakland, California.
Objective: This study aimed to assess short-term neurodevelopmental outcomes for neonates affected by fetomaternal hemorrhage (FMH) and compare them with an unexposed group.
Study Design: A retrospective cohort analysis was conducted within a large integrated medical system spanning from 2008 to 2018. Neurodevelopmental outcomes of neonatal survivors of FMH were compared with matched controls.
Hematol Transfus Cell Ther
November 2024
Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.
Introduction: The incidence of feto-maternal complications is high in women with sickle cell disease. The paucity of high-quality evidence has led to conditional recommendations for transfusional support in pregnant patients. This study aimed to assess if scheduled partial red cell exchanges impact pregnancy outcomes in sickle cell disease patients.
View Article and Find Full Text PDFMedicine (Baltimore)
May 2024
Department of Obstetrics & Gynecology, First Affiliated Hospital of Army Military Medical University, Chongqing, China.
As a rare obstetric disease, fetomaternal hemorrhage (FMH) often causes severe fetal anemia, edema and even death, easily to be confused with severe neonatal asphyxia. Currently, there are several ways to detect or predict FMH, however, most of them are flawed and time-consuming, as well as unsuitable for rapid diagnosis and timely intervention of FMH. To explore the values of umbilical artery blood gas analysis in the rapid diagnosis of FMH, providing basis for rapid guidance of newborn rescue.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!